top of page

Rare Diseases Are Only Rare if You Don't Live With One.®

Exploring Investigational Treatment Option for
Netherton Syndrome


Quoin Pharmaceuticals invites individuals aged 14 and older to participate in two ongoing clinical studies that are evaluating a topically applied drug which is being developed as a potential treatment for Netherton Syndrome (NS).

This investigational drug is applied twice daily to the arms and lower legs over a twelve-week period.

Study Participant Eligibility Requirements:

  • Have genetic test confirming NS or be willing to take at sponsors expense

  • Be 14 years or older

  • Have lesions on arms or lower legs


  • Five required site visits

  • 12 week dosing period

QNRX_about clinical trial option 1.jpeg

Study Options:

1. Open Label Study

Study Requirements: Participants must continue the use of systemic therapy throughout the study.

Learn more about this study.

2. Controlled Clinical Trial

Study Requirements: Participants must discontinue any systemic therapies before enrollment but may continue using topical treatments on non-study areas.

Learn more about this study.


Participants will be compensated for their time and reimbursed for travel expenses.
Interested in participating?


Please Phone:

858-571-1800 ext 151 or,




About Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases. Our commitment extends beyond treatment development to addressing the unmet medical needs of patients, their families, communities, and care teams. Quoin's dynamic pipeline includes four products targeting a range of rare and orphan indications, such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.

Open label Identifier: NCT05789056

Controlled Identifier: NCT05521438

bottom of page